The Myositis Association (TMA) is partnering with the University of Pittsburgh for a new NIH-sponsored study entitled, “Myositis Patient Centered Tele-Research ( My-PACER ).” The investigators of this study (Drs. Rohit Aggarwal, Chester V. Oddis and Siamak Moghadam) have a long-standing interest in myositis. Dr. Aggarwal is also vice chair of TMA’s Medical Advisory Board….
Continue Reading
When retired Yale professor of economics Martin Shubik was diagnosed with inclusion body myositis (IBM) in 2003, very little was known about the disease. At the time, few professional resources had answers to simple questions like “What can I expect from this disease?”
Continue Reading
Corbus Pharmaceuticals is now recruiting dermatomysitis patients for an exciting phase 3 clinical trial for lenabasum. The trial, known as DETERMINE, is designed to evaluate the efficacy and safety of lenabasum for the treatment of dermatomyositis.
Continue Reading
Excitement is building for Corbus Pharmaceutical’s Phase 3 clinical trial testing the safety and effectiveness of their new drug lenabasum in dermatomyositis patients.
Continue Reading
There is good news for IBM patients who want to participate in the arimoclomol clinical trial.
Continue Reading